Innate Pharma S.A.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
40.27 |
45.93 |
89.00 |
154.72 |
86.95 |
149.55 |
| Przychód Δ r/r |
0.00% |
14.06% |
93.78% |
73.85% |
-43.80% |
71.99% |
| Przychód (min) |
12.01 |
13.70 |
26.55 |
46.15 |
25.94 |
44.61 |
| Przychód (max) |
98.81 |
112.70 |
218.38 |
379.65 |
213.35 |
366.95 |
| EBITDA (średnia) |
-16.57 |
-18.90 |
-36.63 |
-63.67 |
-35.78 |
-61.54 |
| EBIT (średnia) |
-25.11 |
-28.64 |
-55.50 |
-96.49 |
-54.22 |
-93.26 |
| EBIT % |
-62.36% |
-62.36% |
-62.36% |
-62.36% |
-62.36% |
-62.36% |
| Zysk netto (średni) |
-29.32 |
-39.12 |
-2.78 |
37.66 |
-62.73 |
-43.35 |
| Zysk netto % |
-72.82% |
-85.17% |
-3.13% |
24.34% |
-72.14% |
-28.99% |
| EPS (średnia) |
-0.36 |
-0.48 |
-0.03 |
0.46 |
-0.77 |
-0.53 |
| Liczba analityków (Przychody) |
3 |
2 |
2 |
1 |
1 |
1 |
| Liczba analityków (EPS) |
2 |
1 |
1 |
1 |
1 |
1 |
| symbol |
IPHA |
IPHA |
IPHA |
IPHA |
IPHA |
IPHA |